These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 2405492)

  • 1. In vivo activation of lymphokine-activated killer activity with interleukin-2: prospects for combination therapies.
    Sosman JA; Hank JA; Sondel PM
    Semin Oncol; 1990 Feb; 17(1 Suppl 1):22-30; discussion 38-41. PubMed ID: 2405492
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Monoclonal antibody therapy of murine lymphoma: enhanced efficacy by concurrent administration of interleukin 2 or lymphokine-activated killer cells.
    Schultz KR; Klarnet JP; Peace DJ; Cheever MA; Badger CC; Bernstein ID; Greenberg PD
    Cancer Res; 1990 Sep; 50(17):5421-5. PubMed ID: 2386946
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interleukin 2 in cancer therapy.
    Testa U; Montesoro E; Bulgarini D; Samoggia P; Masciulli R; Habetswallner D; Carè A; Mariani G; Giannella G; Boccoli G
    Ann Ist Super Sanita; 1990; 26(3-4):283-334. PubMed ID: 2091501
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cancer, cytokines, and cytotoxic cells: interleukin-2 in the immunotherapy of human neoplasms.
    Atzpodien J; Kirchner H
    Klin Wochenschr; 1990 Jan; 68(1):1-11. PubMed ID: 2407894
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Interleukin 2: immunologic background and clinical use in tumor therapy].
    Dummer R; Welters H; Keilholz U; Tilgen W; Burg G
    Hautarzt; 1990 Feb; 41(2):53-5. PubMed ID: 2180854
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The immunotherapy of human cancer with interleukin 2: present status and future directions.
    Kolitz JE; Mertelsmann R
    Cancer Invest; 1991; 9(5):529-42. PubMed ID: 1933486
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of interleukin-2 in cancer therapy.
    Kohler PC; Sondel PM
    Cancer Surv; 1989; 8(4):861-73. PubMed ID: 2701732
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Functional and phenotypic modifications induced by IL-4, as single agent or in combination with IL-2, on PBMC preactivated in vivo by alpha-interferon + interleukin-2 therapy.
    Favrot M; Capdeville R; Combaret V; Zhou DC; Clapisson G; Banchereau J; Franks CR; Chouaib S; Blay JY; Philip T
    Eur Cytokine Netw; 1990; 1(3):141-7. PubMed ID: 2129798
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interleukin-2 in the treatment of renal cancer.
    Margolin KA
    Semin Oncol; 2000 Apr; 27(2):194-203. PubMed ID: 10768598
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An explanation of the variable clinical response to interleukin 2 and LAK cells.
    Parmiani G
    Immunol Today; 1990 Apr; 11(4):113-5. PubMed ID: 2187466
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Cancer therapy by using bispecific antibody].
    Azuma A; Niitani H; Okumura K
    Gan To Kagaku Ryoho; 1991 Aug; 18(10):1535-42. PubMed ID: 1872618
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Experience with the use of high-dose interleukin-2 in the treatment of 652 cancer patients.
    Rosenberg SA; Lotze MT; Yang JC; Aebersold PM; Linehan WM; Seipp CA; White DE
    Ann Surg; 1989 Oct; 210(4):474-84; discussion 484-5. PubMed ID: 2679456
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Influence of various cytokines on the induction of lymphokine-activated killer cells.
    Bergmann L; Weidmann E; Bungert B; Hechler P; Mitrou PS
    Nat Immun Cell Growth Regul; 1990; 9(4):265-73. PubMed ID: 2120581
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Generation propagation, and targeting of human CD4+ helper/killer T cells induced by anti-CD3 monoclonal antibody plus recombinant IL-2. An efficient strategy for adoptive tumor immunotherapy.
    Nishimura T; Nakamura Y; Takeuchi Y; Tokuda Y; Iwasawa M; Kawasaki A; Okumura K; Habu S
    J Immunol; 1992 Jan; 148(1):285-91. PubMed ID: 1345787
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tumor growth suppression by a mouse/human chimeric anti-CEA antibody and lymphokine-activated killer cells in vitro and in SCID mouse xenograft model.
    Senba T; Kuroki M; Arakawa F; Yamamoto T; Kuwahara M; Haruno M; Ikeda S; Matsuoka Y
    Anticancer Res; 1998; 18(1A):17-24. PubMed ID: 9568050
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vivo activation of LAK cells during systemic IL-2 therapy.
    Lang P; Vitté-Mony I; Farace F; Stancou R; Triebel F; Escudier B; Hercend T; Bertoglio J
    Eur Cytokine Netw; 1990; 1(3):185-8. PubMed ID: 2129800
    [No Abstract]   [Full Text] [Related]  

  • 17. Specific adoptive immunotherapy mediated by tumor-draining lymph node cells sequentially activated with anti-CD3 and IL-2.
    Yoshizawa H; Chang AE; Shu S
    J Immunol; 1991 Jul; 147(2):729-37. PubMed ID: 1830072
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Induction of lymphokine activated killer (LAK) and prolongation of its activity by intrasplenic injection of interleukin 2 (IL-2) in combination with tumor necrosis factor (TNF)].
    Nakajima I; Okuno K; Ohnishi H; Shilayama Y; Nakamura T; Hirohata T; Yasutomi M
    Nihon Geka Gakkai Zasshi; 1990 Oct; 91(10):1548-53. PubMed ID: 2263237
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Repetitive weekly cycles of interleukin 2: effect of outpatient treatment with a lower dose of interleukin 2 on non-major histocompatibility complex-restricted killer activity.
    Goldstein D; Sosman JA; Hank JA; Weil-Hillman G; Moore KH; Borchert A; Bechhofer R; Storer B; Kohler PC; Levitt D
    Cancer Res; 1989 Dec; 49(23):6832-9. PubMed ID: 2819723
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prospects for interleukin-2 therapy in hematologic malignant neoplasms.
    Malkovska V; Sondel PM
    J Natl Cancer Inst Monogr; 1990; (10):69-72. PubMed ID: 2189478
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.